英夫利西单抗与生物类似药CT-P13在3112例溃疡性结肠炎患者中的有效性和安全性比较
基于法国全国健康行政数据库的对比性真实世界等效性队列研究,纳入2015年1月1日至2017年6月30日期间3112例未使用过英夫利西单抗的溃疡性结肠炎患者,比较CT-P13与参照药英夫利西单抗的有效性和安全性。主要复合终点显示CT-P13与参照药等效(HR 1.04;95%CI 0.94-1.15),CT-P13组严重感染数更低(HR 0.65;95%CI 0.48-0.88),实体或血液系统恶性肿瘤发生率无差异(HR 0.81;95%CI 0.41-1.60)。
要点
- 在未使用过英夫利西单抗的溃疡性结肠炎患者中,CT-P13的有效性与参照药等效(HR 1.04;95%CI 0.94-1.15)。
- CT-P13组严重感染数低于参照药组(HR 0.65;95%CI 0.48-0.88)。
- 两组实体或血液系统恶性肿瘤发生率无差异(HR 0.81;95%CI 0.41-1.60)。
核心结论
- 对于未使用过英夫利西单抗的溃疡性结肠炎患者,CT-P13的有效性与参照药等效,且严重感染风险可能更低。
研究设计与样本
- 对比性真实世界等效性队列研究,使用法国全国健康行政数据库,纳入2015年1月1日至2017年6月30日期间3112例15岁以上、无其他英夫利西单抗适应证的未使用过英夫利西单抗的溃疡性结肠炎患者。
主要发现
- 共纳入3112例患者,参照药组1434例,CT-P13组1678例。
- 参照药组710例和CT-P13组743例达到主要复合终点(死亡、溃疡性结肠炎相关手术、全因住院和其他生物制剂报销)。
- 多变量分析中,CT-P13主要终点与参照药等效(HR 1.04;95%CI 0.94-1.15)。
- CT-P13组严重感染数低于参照药组(HR 0.65;95%CI 0.48-0.88)。
- 两组实体或血液系统恶性肿瘤发生率无差异(HR 0.81;95%CI 0.41-1.60)。
关键数值与推荐
- 等效性定义为CT-P13与参照药风险比(HR)的95%CI在多变量边际Cox模型预设范围内(0.80-1.25)。
- 主要复合终点包括死亡、溃疡性结肠炎相关手术、全因住院和其他生物制剂报销。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CT-P13, a biosimilar of the reference product infliximab, has been approved for the treatment of ulcerative colitis on the basis of the results of trials conducted in patients with spondyloarthritis and rheumatoid arthritis. AIM: To compare the effectiveness and safety of CT-P13 and the reference product in infliximab-naive patients with ulcerative colitis METHODS: A comparative real-life equivalence cohort study was conducted using the French nationwide health administrative database. Infliximab-naive patients with ulcerative colitis over 15 years of age who started infliximab with no other indications for infliximab were included. The primary outcome was a composite endpoint (death, ulcerative colitis-related surgery, all-cause hospitalisation and reimbursement for other biologics). Equivalence was defined as a 95% CI of the hazard ratio (HR) of CT-P13 vs the reference product, in a multivariable marginal Cox model situated within prespecified margins of (0.80-1.25). RESULTS: A total of 3112 patients were included between 1 January 2015 and 30 June 2017: 1434 received the reference product, 1678 received CT-P13. Overall, 710 patients in the reference product group and 743 patients in the CT-P13 group met the composite endpoint. In multivariable analysis of the primary outcome, CT-P13 was equivalent to the reference product (HR 1.04; 95% CI: 0.94-1.15). The number of serious infections was lower in the CT-P13 group (HR 0.65; 95% CI: 0.48-0.88). There was no difference in the incidence of solid or haematologic malignancy (HR 0.81; 95% CI: 0.41-1.60). CONCLUSIONS: The effectiveness of CT-P13 is equivalent and the risk of serious infections could be lower than that of the reference product for infliximab-naive patients with ulcerative colitis.
引用
- Meyer A, Rudant J, Drouin J, et al. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther. 2019. PMID: 31115919. doi:10.1111/apt.15323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。